식품 알레르기 치료 시장 예측(-2030년) : 알레르겐 유형별, 약물 유형별, 투여 경로별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Food Allergy Treatment Market is accounted for $7.13 billion in 2024 and is expected to reach $12.81 billion by 2030 growing at a CAGR of 10.27% during the forecast period. Food allergy treatment primarily focuses on managing symptoms and preventing severe reactions. The best strategy is to stay away from trigger foods, but this can be difficult because allergens are present in many different foods. While epinephrine (adrenaline) injections are essential for treating anaphylaxis, a potentially fatal allergic reaction, medications such as antihistamines and corticosteroids may be used to relieve mild symptoms. Immunotherapy is another recent development in the treatment of food allergies, in which patients are exposed to trace amounts of the allergen over time to develop tolerance.

According to the World Allergy Organization (WAO), approximately 220-250 million people globally suffer from food allergies, with the highest prevalence seen in children under the age of 5.

Market Dynamics:

Driver:

Growing food allergy prevalence

Food allergies have been becoming more and more common worldwide, especially in developed areas like North America and Europe. Research shows that a sizable percentage of kids suffer from food allergies; estimates range as high as 8% for this population. The number of food allergy diagnoses is rising due to a number of factors, including genetics, dietary changes, increased exposure to processed foods, and decreased exposure to some environmental factors (hygiene hypothesis). Moreover, the increase in cases is raising the need for efficient therapies that can help patients manage their symptoms and enhance their quality of life.

Restraint:

Expensive advanced medical care

The high cost of advanced therapies, like immunotherapy and biologics, which, although effective, often require long-term administration and close medical supervision, resulting in substantial healthcare costs, is one of the major challenges facing the food allergy treatment market. Immunotherapy treatments can take months or even years to show results, and biologics, such as monoclonal antibodies, are typically expensive to produce and administer. Additionally, the cost can be a barrier for many patients, especially those in low-income regions or those without adequate health insurance coverage, which limits access to advanced therapies and prevents their widespread adoption.

Opportunity:

Development of tailored therapy methods

The treatment of food allergies is increasingly being approached through personalized medicine. Genetic testing is one of the more advanced diagnostic tools that have made it possible for medical professionals to create customized treatment programs that are suited to each patient's unique allergies. Biologics and immunotherapy are two examples of treatments that benefit from this strategy. Personalized food allergy treatments are also a more appealing option for patients because they provide a more focused approach with fewer side effects. Furthermore, the increasing emphasis on precision medicine and genomics is anticipated to spur additional advancements in food allergy therapies, creating new opportunities for market expansion.

Threat:

Intense competition from existing therapies

The fierce competition from current treatments is one of the major risks facing the market for food allergy treatments. For the management of food allergy reactions, the market offers a wide range of well-established treatments, such as corticosteroids, epinephrine injections, and antihistamines. Because these treatments are well-known and reasonably priced, it is difficult for more recent and costly treatments like immunotherapy and biologics to increase their market share. Moreover, the fierce competition created by the widespread availability of generic versions of these well-known medications makes it more difficult for new products to take off unless they provide noticeably better advantages or are more affordable.

Covid-19 Impact:

The market for food allergy treatments was significantly impacted by the COVID-19 pandemic, both positively and negatively. On the one hand, the pandemic raised people's awareness of health-related problems, such as food allergies, as they learned to manage their general well-being and immunity in unpredictable times. But the crisis also caused problems for healthcare systems, causing many patients' regular doctor's appointments, allergy tests, and treatments to be postponed. Clinical trials and non-essential procedures were delayed, which had an impact on the creation and accessibility of novel treatments. Furthermore, a lot of patients had trouble getting in-person consultations, especially in areas with stringent lockdowns, which caused delays in diagnosis and treatment.

The Tree Nuts segment is expected to be the largest during the forecast period

The food allergy treatment market is expected to be largest share by the tree nuts segment. Since tree nuts like cashews, walnuts, and almonds are among the most common allergens, there is a greater need for efficient treatment solutions. The broad awareness of tree nut allergies, which can result in severe reactions, including anaphylaxis, is what propels the segment's dominance. As a result, allergy treatments like epinephrine injections and oral immunotherapy have been developed to control and lessen allergic reactions. Additionally, the expansion of this market segment within the larger food allergy treatment market is being driven by developments in medical research and treatments designed especially to address tree nut allergies.

The Immunotherapy segment is expected to have the highest CAGR during the forecast period

In the food allergy treatment market, the immunotherapy segment is anticipated to grow at the highest CAGR. Because immunotherapy has the ability to gradually desensitize patients to allergens, it is becoming increasingly popular, especially oral immunotherapy (OIT) and sublingual immunotherapy (SLIT). By fostering tolerance to food allergens, this therapeutic strategy considerably lowers the likelihood of severe allergic reactions. Immunotherapy provides long-term benefits for patients with food allergies, including those to common allergens like peanuts, tree nuts, and shellfish, as clinical research continues to advance and more treatments are approved by regulators.

Region with largest share:

The Food Allergy Treatment Market is expected to be the largest share by the North American region. The main cause of this is the high incidence of food allergies, especially in children, in nations like the US and Canada. Additionally, the area benefits from a strong emphasis on medical research and innovation, a sophisticated healthcare infrastructure, and general awareness of food allergies. North America leads the market in terms of revenue and adoption of food allergy treatments due to ongoing clinical trials, regulatory approvals, and the development of innovative treatments like immunotherapy. Moreover, the region's dominant market position is facilitated by the expanding availability of epinephrine injectors and over-the-counter antihistamines.

Region with highest CAGR:

The food allergy treatment market is anticipated to grow at the highest CAGR in the Asia Pacific (APAC) region. In nations like China, India, Japan, and South Korea, growing urbanization, dietary changes, and growing awareness of food allergies are the main causes of this growth. The need for treatments like antihistamines, epinephrine injectors, and newer therapies like immunotherapy is rising as food allergies are acknowledged as a serious health issue. Furthermore, APAC is now the region with the fastest rate of growth in the food allergy treatment industry owing to rising healthcare investments and advancements in medical infrastructure throughout the region.

Key players in the market

Some of the key players in Food Allergy Treatment market include Alladapt Immunotherapeutics, Inc., F. Hoffman-La Roche Ltd., Prota Therapeutics Pty Ltd, COUR Pharmaceuticals Development Company, Inc, Novartis Pharmaceuticals, Teva Pharmaceutical Industries Ltd., DBV Technologies, Stallergenes Greer International AG, Aravax, Vedanta Biosciences, Inc., Sanofi, Neogen Corporation, AstraZeneca, Mylan N.V. and Cambridge Allergy Ltd.

Key Developments:

In December 2024, Teva Pharmaceutical Industries Ltd. announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.

In September 2024, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet medical needs in cancer, and Orano Med, a French clinical-stage biotechnology company, subsidiary of the Orano Group, developing lead-212 (212Pb) radioligand therapies (RLTs) against cancer.

In February 2024, Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology.

Allergen Types Covered:

• Dairy Products
• Poultry Products
• Tree Nuts
• Peanuts
• Shellfish
• Wheat
• Soys
• Other Allergen Types

Drug Types Covered:

• Antihistamines
• Decongestants
• Corticosteroids
• Mast Cell Stabilizers
• Leukotriene Inhibitors
• Nasal Anti-cholinergic
• Immuno-modulators
• Epinephrine
• Immunotherapy
• Other Drug Types

Route of Administrations Covered:

• Oral
• Parenteral
• Other Route of Administrations

End Users Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Food Allergy Treatment Market, By Allergen Type

• 5.1 Introduction
• 5.2 Dairy Products
• 5.3 Poultry Products
• 5.4 Tree Nuts
• 5.5 Peanuts
• 5.6 Shellfish
• 5.7 Wheat
• 5.8 Soys
• 5.9 Other Allergen Types

6 Global Food Allergy Treatment Market, By Drug Type

• 6.1 Introduction
• 6.2 Antihistamines
• 6.3 Decongestants
• 6.4 Corticosteroids
• 6.5 Mast Cell Stabilizers
• 6.6 Leukotriene Inhibitors
• 6.7 Nasal Anti-cholinergic
• 6.8 Immuno-modulators
• 6.9 Epinephrine
• 6.10 Immunotherapy
• 6.11 Other Drug Types

7 Global Food Allergy Treatment Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other Route of Administrations

8 Global Food Allergy Treatment Market, By End User

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Retail Pharmacies
• 8.4 Other End Users

9 Global Food Allergy Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Alladapt Immunotherapeutics, Inc.
• 11.2 F. Hoffman-La Roche Ltd.
• 11.3 Prota Therapeutics Pty Ltd
• 11.4 COUR Pharmaceuticals Development Company, Inc
• 11.5 Novartis Pharmaceuticals
• 11.6 Teva Pharmaceutical Industries Ltd.
• 11.7 DBV Technologies
• 11.8 Stallergenes Greer International AG
• 11.9 Aravax
• 11.10 Vedanta Biosciences, Inc.
• 11.11 Sanofi
• 11.12 Neogen Corporation
• 11.13 AstraZeneca
• 11.14 Mylan N.V.
• 11.15 Cambridge Allergy Ltd.